Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Current Leases (2019 - 2025)

Seres Therapeutics' Current Leases history spans 7 years, with the latest figure at $9.9 million for Q3 2025.

  • For Q3 2025, Current Leases changed N/A year-over-year to $9.9 million; the TTM value through Sep 2025 reached $9.9 million, changed N/A, while the annual FY2024 figure was $8.7 million, 55.25% up from the prior year.
  • Current Leases for Q3 2025 was $9.9 million at Seres Therapeutics, up from $9.5 million in the prior quarter.
  • Across five years, Current Leases topped out at $9.9 million in Q3 2025 and bottomed at $3.6 million in Q4 2022.
  • The 5-year median for Current Leases is $6.6 million (2021), against an average of $7.0 million.
  • The largest annual shift saw Current Leases tumbled 45.52% in 2022 before it skyrocketed 68.1% in 2024.
  • A 5-year view of Current Leases shows it stood at $6.6 million in 2021, then crashed by 45.52% to $3.6 million in 2022, then surged by 55.15% to $5.6 million in 2023, then surged by 55.25% to $8.7 million in 2024, then increased by 14.36% to $9.9 million in 2025.
  • Per Business Quant, the three most recent readings for MCRB's Current Leases are $9.9 million (Q3 2025), $9.5 million (Q2 2025), and $8.7 million (Q4 2024).